LAVA Therapeutics (NASDAQ:LVTX) Issues Quarterly Earnings Results, Beats Estimates By $0.18 EPS

LAVA Therapeutics (NASDAQ:LVTX) issued its quarterly earnings results on Friday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.18, Zacks reports. The business had revenue of $2.50 million during the quarter, compared to analyst estimates of $2.40 million.

LAVA Therapeutics Trading Down 0.8 %

NASDAQ:LVTX traded down $0.01 during mid-day trading on Friday, hitting $1.29. The company had a trading volume of 43,333 shares, compared to its average volume of 173,459. The business has a fifty day simple moving average of $1.13 and a 200-day simple moving average of $1.37. The firm has a market capitalization of $33.92 million, a price-to-earnings ratio of -1.25 and a beta of 0.48. LAVA Therapeutics has a 1 year low of $0.85 and a 1 year high of $3.57.

Wall Street Analyst Weigh In

LVTX has been the topic of several recent analyst reports. Leerink Partners reiterated a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Leerink Partnrs downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. JMP Securities reiterated a “market perform” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $1.50 price objective (down from $2.00) on shares of LAVA Therapeutics in a research note on Thursday, February 27th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $3.17.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.